Insights  /  Market Access
Pharma · Reimbursement

AMNOG explained: how Germany prices a new medicine

A marketing authorization lets you sell. AMNOG decides what Germany will pay — and for most launches, it sets the ceiling on revenue before the sales force ever gets going. Here's how the process actually works.

10 min read Reviewed by Ralf Müller, Market Access & Regulatory Lead Updated 2026
In one paragraph

A new patented medicine launches in Germany at a free price, then goes through AMNOG: you file a benefit dossier, the IQWiG rates its added benefit against a defined comparator, the G-BA issues a resolution, and the statutory insurers (GKV-Spitzenverband) negotiate a reimbursement price (Erstattungsbetrag). Demonstrated added benefit buys pricing room; none usually means a reference-price ceiling. This single process — not your home-market price — sets what Germany pays.

What AMNOG is

AMNOG — the Arzneimittelmarktneuordnungsgesetz, in force since 2011 — is the German system for assessing the benefit of new patented medicines and setting their reimbursed price.

Before AMNOG, manufacturers set prices freely and the statutory system largely paid them. AMNOG changed that: a new drug still launches at a free price, but from then on its price has to be justified by evidence of added benefit over the existing standard of care. The result is not a yes/no market-access gate — the drug is reimbursable throughout — but a price gate that shapes the entire commercial case.

Getting authorized and getting a price are two different projects. AMNOG is the second one.

The pathway

How a price gets set, step by step

From launch to a binding reimbursement price is roughly a year. The clock and the comparator are fixed early; the evidence you bring decides the outcome.

01

Launch at a free price

On market entry you set the price yourself. This window is short — and since the 2023 reform the negotiated price applies retroactively from month 7, so the free-price period is a revenue lever, not a lasting one.

02

File the benefit dossier

Within the required window you submit a dossier to the G-BA (Federal Joint Committee) documenting the drug's added benefit against the comparator.

03

IQWiG assesses added benefit

The IQWiG evaluates the evidence and rates the added benefit (Zusatznutzen) versus the zweckmaessige Vergleichstherapie — the appropriate comparator. This is where most of the value is won or lost.

04

G-BA resolution

The G-BA issues a formal resolution on the added-benefit category (see below). It also defines the patient subpopulations to which each rating applies.

05

Price negotiation — and, if needed, arbitration

The GKV-Spitzenverband negotiates the reimbursement amount (Erstattungsbetrag). No agreement within the deadline goes to an arbitration board (Schiedsstelle). The outcome then forks:

Added benefit shown
Negotiated premium A price reflecting the demonstrated benefit — room above the reference floor, anchored to the comparator's cost and European reference prices.
No added benefit
Reference-price ceiling Typically a Festbetrag group or a price not exceeding the comparator — a hard cap set before you have recovered the cost base.

Added-benefit categories

The IQWiG assessment and the G-BA resolution place the drug into one of six categories — and the rating is made separately for each patient subpopulation, so one drug can hold different ratings at once.

Rating
What it means for pricing
Major (erheblich)
Strongest hand — substantial, sustained improvement. Best negotiating position.
Considerable (betraechtlich)
A meaningful improvement — the most common “good” outcome; solid premium room.
Minor (gering)
A modest but real benefit — limited premium.
Non-quantifiable
Benefit shown but not gradable from the evidence — negotiated case by case.
Not proven
Evidence didn't demonstrate added benefit — usually the comparator's price level.
Less benefit
Worse than the comparator — the weakest position, price pressure below reference.

The negotiation is anchored to these ratings, the annual cost of the comparator, and prices for the same drug in a basket of European countries. A strong rating in a large subpopulation is worth far more than a strong rating in a niche one — which is why the target population defined in the dossier is a strategic choice, not a formality.

What changed: the 2023 reform

The GKV-Finanzstabilisierungsgesetz (GKV-FinStG) tightened AMNOG to control statutory spending. If your last German data is older, these are the shifts that matter most:

  • Price applies from month 7. The negotiated Erstattungsbetrag now takes effect from the seventh month after launch (previously month 13) — shortening the free-price window.
  • Guardrails (Leitplanken). The reform introduced firmer upper limits tying negotiated prices to the added-benefit rating and the comparator — less room for drugs with weak or no added benefit.
  • Combination discount. An additional mandatory discount applies to certain drug combinations.
  • Orphan threshold lowered. The revenue threshold above which orphan drugs must undergo full benefit assessment was reduced (to the order of €30M), pulling more orphans into the full process sooner.

Thresholds and rules are reformed periodically. Treat specific figures as indicative and confirm the current position for your product before you plan around them.

Where companies go wrong

  • Treating AMNOG as a post-launch formality. By the time the dossier is due, the evidence is fixed. The ceiling is discovered after the cost base is built.
  • Ignoring the comparator until it's too late. The zVT should shape the pivotal trial, not surprise you at submission.
  • Optimising for the label, not the subpopulation. A broad approval with a weak rating in the largest subgroup can be worth less than a focused one with a strong rating.
  • Assuming the home-market price transfers. European reference pricing means a low price set in one market can follow the drug across the EU.

In Germany, market access is structure before visibility. The reimbursement case should be built into the plan from day one — not bolted on at launch.

RM
Reviewed by Ralf Müller
Market Access & Regulatory Lead · 15 years in German pharma
Planning a German launch?

We turn AMNOG from a surprise into a strategy.

In a focused session we map your realistic added-benefit scenario, the likely comparator, and the commercial model that fits — before you commit budget. We own the market-access read and orchestrate the dossier with specialist partners.